Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA
Chemotherapy-refractive multiple myeloma (MM) is serious and life-threatening, and better treatments are urgently needed. BCMA is a prominent marker on the cell surface of MM cells, rendering it an accepted target for antibody therapy. Considering that MM is a liquid tumor and immunotherapy has enjo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Immuno |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5601/3/2/16 |